Clinical Evidence: What the Research Shows About GLP-1 Results The STEP clinical trials demonstrated that semaglutide injection produced average weight loss of 15-18% over 68 weeks in people with obesity, with some participants achieving losses exceeding 20%
Rather than aiming for artificial elevation, modern stacks emphasize nutrient timing, amino acid availability, and hormonal support pathways that align with natural secretion cycles
Higher concentration means stronger receptor activation
Wang J, Chen L, Li P, et al
The body is simultaneously adjusting to reduced caloric intake, new blood sugar patterns, altered gastric emptying, and the neurological effects of GLP-1 and GIP receptor activation
doi: 10.1186/s12958-023-01159-6